These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 38682846

  • 1. Antifungal susceptibility of molecularly confirmed Aspergillus species from clinical samples.
    Tzar MN, Mustakim S, Yusoff H, Tap RM.
    Malays J Pathol; 2024 Apr; 46(1):71-78. PubMed ID: 38682846
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
    Wang HC, Hsieh MI, Choi PC, Wu CJ.
    J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
    [Abstract] [Full Text] [Related]

  • 3. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
    Öz Y, Özdemir HG, Gökbolat E, Kiraz N, Ilkit M, Seyedmousavi S.
    Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
    [Abstract] [Full Text] [Related]

  • 4. Prospective survey of Aspergillus species isolated from clinical specimens and their antifungal susceptibility: A five-year single-center study in Japan.
    Toyotome T, Saito S, Koshizaki Y, Komatsu R, Matsuzawa T, Yaguchi T.
    J Infect Chemother; 2020 Feb; 26(2):321-323. PubMed ID: 31564504
    [Abstract] [Full Text] [Related]

  • 5. Molecular Identification and In Vitro Antifungal Susceptibility of Aspergillus Isolates Recovered from Otomycosis Patients in Western China.
    Zhang L, Wang X, Houbraken J, Mei H, Liao W, Hasimu H, Liu W, Deng S.
    Mycopathologia; 2020 Jun; 185(3):527-535. PubMed ID: 32346838
    [Abstract] [Full Text] [Related]

  • 6. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
    Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH.
    J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST).
    Arendrup MC, Friberg N, Mares M, Kahlmeter G, Meletiadis J, Guinea J, Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST).
    Clin Microbiol Infect; 2020 Nov; 26(11):1464-1472. PubMed ID: 32562861
    [Abstract] [Full Text] [Related]

  • 9. Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.
    Mello E, Posteraro B, Vella A, De Carolis E, Torelli R, D'Inzeo T, Verweij PE, Sanguinetti M.
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28416538
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Antifungal susceptibilities of Aspergillus spp. strains isolated from invasive aspergillosis cases].
    Gürcan S, Tikveşli M, Eryildiz C, Evci C, Ener B.
    Mikrobiyol Bul; 2010 Apr; 44(2):273-8. PubMed ID: 20549962
    [Abstract] [Full Text] [Related]

  • 13. Antifungal Susceptibility of the Aspergillus viridinutans Complex: Comparison of Two In Vitro Methods.
    Lyskova P, Hubka V, Svobodova L, Barrs V, Dhand NK, Yaguchi T, Matsuzawa T, Horie Y, Kolarik M, Dobias R, Hamal P.
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437620
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Species identification and antifungal susceptibility testing of Aspergillus strains isolated from patients with otomycosis in northern China.
    Jing R, Yang WH, Xiao M, Li Y, Zou GL, Wang CY, Li XW, Xu YC, Hsueh PR.
    J Microbiol Immunol Infect; 2022 Apr; 55(2):282-290. PubMed ID: 33839057
    [Abstract] [Full Text] [Related]

  • 16. In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of Aspergillus Nigri Complex.
    Badali H, Fakhim H, Zarei F, Nabili M, Vaezi A, Poorzad N, Dolatabadi S, Mirhendi H.
    Mycopathologia; 2016 Apr; 181(3-4):235-40. PubMed ID: 26615417
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Drug Sensitivity and Resistance Mechanism in Aspergillus Section Nigri Strains from Japan.
    Hashimoto A, Hagiwara D, Watanabe A, Yahiro M, Yikelamu A, Yaguchi T, Kamei K.
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607016
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P.
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.